CONTRAFECT CORPORATION CONTRAFECT CORPORATION SHARES UP 19.9% AFTER Q1 LOSS NARROWS
Contrafect Corporation Shares Up 19.9% After Q1 Loss Narrows…
May 15, 2023 at 12:54 pm
Share
Share
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0185 USD | +12.12% |
|
+52.89% | -38.33% |
| 05-03 | North American Morning Briefing : Apple, Amgen -2- | DJ |
| 04-26 | North American Morning Briefing : Tech Still in -2- | DJ |
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its CF-301 is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.
Calendar
2024-08-08
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -38.33% | 177K | |
| +41.79% | 50.93B | |
| -0.56% | 42.12B | |
| +49.62% | 42.05B | |
| -7.20% | 29.18B | |
| +12.59% | 26.02B | |
| -21.51% | 18.9B | |
| +6.92% | 13.21B | |
| +24.91% | 12.17B | |
| +29.60% | 12.16B |
- Stock Market
- Equities
- CFRXQ Stock
- News ContraFect Corporation
- Contrafect Corporation Shares Up 19.9% After Q1 Loss Narrows…
